search
Back to results

Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease

Primary Purpose

Sciatica, Back Pain

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
DIAM™ Spinal Stabilization System
Herniectomy
Sponsored by
Medtronic Spinal and Biologics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sciatica

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has a history of sciatica (radicular pain) for at least 6 weeks, but not more than 1 year secondary to one symptomatic lumbar disc herniation at the levels L2-L5 as confirmed by patient history and clinical evaluation, and without major neurological impairment (i.e. not less than M 3/5; Medical Research Council Classification);
  • Has a history of continuous low back pain for no more than 1 year secondary to lumbar degenerative disc disease (intermittent back pain may occur for more than a year);
  • Has pre-treatment back pain score greater than or equal to 3, concomitant with leg pain score greater than or equal to 6. Leg pain score must be greater than back pain score (pain intensity score measured on a 10 cm VAS scale);
  • Has one symptomatic disc herniation: protrusion, extrusion or sequestration (Milette & Fardon, 2001) as confirmed by MRI at the target level;
  • Evidence of disc degeneration ≤ Grade IV at the target and adjacent levels as confirmed by MRI (Pfirrmann, 2001);
  • Has an Oswestry Disability Index (ODI) score ≥ 34%;
  • Has been treated non-operatively (e.g. bed rest, physical therapy, medications, TENS, manipulation, hydrotherapy, acupressure/acupuncture, massage, bracing and/or spinal injections) for at least 6 continuous weeks unless strong clinical grounds for expediting surgery;
  • Patient male or female, age 20-60 years inclusive and is skeletally mature;
  • Is willing and able to comply with the study plan and able to provide an informed consent;

Exclusion Criteria:

  • Has a primary diagnosis of spinal disorder other than degenerative disc at the involved level;
  • Has a symptomatic disc herniation at more than one lumbar level;
  • Requires a herniectomy at more than one lumbar level;
  • Has a disc degeneration at the treated and adjacent levels > Grade IV (Pfirrmann, 2001);
  • Has a decrease of disc height ≥ 30% as measured by the center of the disc space, and compared to the disc space at the next superior spinal level;
  • Has Modic changes on MRI greater than Grade I at the target level;
  • Has Modic changes on MRI at the adjacent levels;
  • Has an advanced degree of retrolisthesis as shown by lateral X-rays (> 25%, i.e. grade I as per Meyerding);
  • Has a clinical evidence of lysis, antero listhesis or scoliosis (Cobb angle more than 10°);
  • Has signs of segmental instability: more than 4 mm of translation or more than 10° angular motion between adjacent end plates (comparing flexion and extension views);
  • Has congenital or iatrogenic posterior element insufficiency (e.g. facet resection, spondylolysis, pars fracture, or Spinal Bifida Occulta);
  • Has had any previous lumbar spine surgery;
  • Has a Waddell signs of inorganic behaviour score greater than or equal to 3;
  • Has evidence of an active disruptive psychiatric disorder, cognitive impairment or other known condition, significant enough to impact the perception of pain, precludes surgical procedure, clinical evaluation and/or ability to evaluate treatment outcome as determined by investigator;
  • Has a known allergy to silicone, polyethylene, or titanium;
  • Is an alcohol and /or drug abuser, as defined by currently undergoing treatment for alcohol and/or drug abuse;
  • Has obesity defined by BMI greater than or equal to 35;
  • Inability to complete the questionnaires;
  • Planned pregnancy during the course of the study;
  • Previous enrollment into a spine study;
  • Vulnerable patients or unable to exercise free informed consent;

Sites / Locations

  • Cliniques Universitaires Bruxelles Hôpital Erasme
  • AZ Sint-Lucas
  • Hôpital de la Citadelle
  • AZ Sint-Elisabeth Hospital
  • University Hospital Olomouc, dept of Neurosurgery
  • Otto-Von-Guericke Universität
  • CA NCH Klinikum rechts der Isar/München
  • Medizinisches Zentrum Kreis Aachen
  • Anthea Casa di Cura
  • Istituto Ortopedico Galeazzi
  • St. Luke Hospital, University of Rzeszow, dept of Neurosurgery
  • Hospital Universitari Bellvitge
  • Hospital de León
  • Hôpital Fribourgeois
  • Hôpitaux Universitaires de Genève
  • Hirslanden Klinik St. Anna
  • Chase Farm Hospital
  • St. Georges Hospital
  • Greater Manchester Neuroscience Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Investigational group

Control group

Arm Description

Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System

Single level herniectomy

Outcomes

Primary Outcome Measures

To Demonstrate a Statistically Significant Difference in the Relief of Back Pain Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and 6-month of the Patient's Back-pain Score on a Visual Analogue Scale (VAS).
The endpoint will be the difference between baseline and 6 months of the patient's back-pain score on a Visual Analogue Scale (VAS). A standardized visual analogue scale (0cm-10cm; with 0cm meaning 'no pain' and 10cm meaning 'worst possible pain') will be used. Large values of the VAS score represent large degree of pain. Large (negative) change in VAS score (6 months - baseline) represents large relief of pain. For treated subjects, all analyses except the safety analyses, Intent-To-Treat population will serve as the primary analysis dataset.

Secondary Outcome Measures

To Demonstrate a Statistically Significant Difference in the Reduction of Disability Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and 12 Months of the Patient's Score on the Oswestry Disability Index (ODI).
The endpoint will be the difference between baseline and 12 months of the patient's score on the Oswestry Disability Index (ODI). The ODI is a low back pain disability questionnaire used to measure a patient's permanent functional disability in a scale from 0 to 50 (when all the 10 sections are answered); large ODI scores indicate large disability.

Full Information

First Posted
September 9, 2008
Last Updated
January 26, 2016
Sponsor
Medtronic Spinal and Biologics
search

1. Study Identification

Unique Protocol Identification Number
NCT00749996
Brief Title
Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease
Official Title
Herniectomy vs. Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
June 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Spinal and Biologics

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims at assessing the short and long-term effectiveness and patient perception of benefit with the use of a DIAM™ Spinal Stabilization System in the treatment of complex disc disease at a single level from L2 to L5.
Detailed Description
This study is a multi-center, prospective, randomized, controlled trial. Patients will be randomized in 2 groups: Investigational group: a single level herniectomy procedure, followed by placement of the DIAMTM Spinal Stabilization System; Control group: a single level herniectomy procedure; After surgery, patients will be followed for a 2 years period with required follow up visits at 6 weeks, 3 months, 6 months, 1 year, 2 years and 4 years (optional visit).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sciatica, Back Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
165 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Investigational group
Arm Type
Experimental
Arm Description
Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Single level herniectomy
Intervention Type
Device
Intervention Name(s)
DIAM™ Spinal Stabilization System
Intervention Description
The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
Intervention Type
Procedure
Intervention Name(s)
Herniectomy
Intervention Description
Herniectomy is defined as the "removal of the extruded/protruded/sequestrated disc material". This is done by probing the annulus and disc space and removing all mobile disc fragments.
Primary Outcome Measure Information:
Title
To Demonstrate a Statistically Significant Difference in the Relief of Back Pain Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and 6-month of the Patient's Back-pain Score on a Visual Analogue Scale (VAS).
Description
The endpoint will be the difference between baseline and 6 months of the patient's back-pain score on a Visual Analogue Scale (VAS). A standardized visual analogue scale (0cm-10cm; with 0cm meaning 'no pain' and 10cm meaning 'worst possible pain') will be used. Large values of the VAS score represent large degree of pain. Large (negative) change in VAS score (6 months - baseline) represents large relief of pain. For treated subjects, all analyses except the safety analyses, Intent-To-Treat population will serve as the primary analysis dataset.
Time Frame
6 Months
Secondary Outcome Measure Information:
Title
To Demonstrate a Statistically Significant Difference in the Reduction of Disability Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and 12 Months of the Patient's Score on the Oswestry Disability Index (ODI).
Description
The endpoint will be the difference between baseline and 12 months of the patient's score on the Oswestry Disability Index (ODI). The ODI is a low back pain disability questionnaire used to measure a patient's permanent functional disability in a scale from 0 to 50 (when all the 10 sections are answered); large ODI scores indicate large disability.
Time Frame
12 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has a history of sciatica (radicular pain) for at least 6 weeks, but not more than 1 year secondary to one symptomatic lumbar disc herniation at the levels L2-L5 as confirmed by patient history and clinical evaluation, and without major neurological impairment (i.e. not less than M 3/5; Medical Research Council Classification); Has a history of continuous low back pain for no more than 1 year secondary to lumbar degenerative disc disease (intermittent back pain may occur for more than a year); Has pre-treatment back pain score greater than or equal to 3, concomitant with leg pain score greater than or equal to 6. Leg pain score must be greater than back pain score (pain intensity score measured on a 10 cm VAS scale); Has one symptomatic disc herniation: protrusion, extrusion or sequestration (Milette & Fardon, 2001) as confirmed by MRI at the target level; Evidence of disc degeneration ≤ Grade IV at the target and adjacent levels as confirmed by MRI (Pfirrmann, 2001); Has an Oswestry Disability Index (ODI) score ≥ 34%; Has been treated non-operatively (e.g. bed rest, physical therapy, medications, TENS, manipulation, hydrotherapy, acupressure/acupuncture, massage, bracing and/or spinal injections) for at least 6 continuous weeks unless strong clinical grounds for expediting surgery; Patient male or female, age 20-60 years inclusive and is skeletally mature; Is willing and able to comply with the study plan and able to provide an informed consent; Exclusion Criteria: Has a primary diagnosis of spinal disorder other than degenerative disc at the involved level; Has a symptomatic disc herniation at more than one lumbar level; Requires a herniectomy at more than one lumbar level; Has a disc degeneration at the treated and adjacent levels > Grade IV (Pfirrmann, 2001); Has a decrease of disc height ≥ 30% as measured by the center of the disc space, and compared to the disc space at the next superior spinal level; Has Modic changes on MRI greater than Grade I at the target level; Has Modic changes on MRI at the adjacent levels; Has an advanced degree of retrolisthesis as shown by lateral X-rays (> 25%, i.e. grade I as per Meyerding); Has a clinical evidence of lysis, antero listhesis or scoliosis (Cobb angle more than 10°); Has signs of segmental instability: more than 4 mm of translation or more than 10° angular motion between adjacent end plates (comparing flexion and extension views); Has congenital or iatrogenic posterior element insufficiency (e.g. facet resection, spondylolysis, pars fracture, or Spinal Bifida Occulta); Has had any previous lumbar spine surgery; Has a Waddell signs of inorganic behaviour score greater than or equal to 3; Has evidence of an active disruptive psychiatric disorder, cognitive impairment or other known condition, significant enough to impact the perception of pain, precludes surgical procedure, clinical evaluation and/or ability to evaluate treatment outcome as determined by investigator; Has a known allergy to silicone, polyethylene, or titanium; Is an alcohol and /or drug abuser, as defined by currently undergoing treatment for alcohol and/or drug abuse; Has obesity defined by BMI greater than or equal to 35; Inability to complete the questionnaires; Planned pregnancy during the course of the study; Previous enrollment into a spine study; Vulnerable patients or unable to exercise free informed consent;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ferdiand Krappel, Dr.
Organizational Affiliation
Spitalzentrum Oberwallis, Brig
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cliniques Universitaires Bruxelles Hôpital Erasme
City
Brussels
Country
Belgium
Facility Name
AZ Sint-Lucas
City
Gent
Country
Belgium
Facility Name
Hôpital de la Citadelle
City
Liège
Country
Belgium
Facility Name
AZ Sint-Elisabeth Hospital
City
Zottegem
Country
Belgium
Facility Name
University Hospital Olomouc, dept of Neurosurgery
City
Olomouc
Country
Czech Republic
Facility Name
Otto-Von-Guericke Universität
City
Magdeburg
Country
Germany
Facility Name
CA NCH Klinikum rechts der Isar/München
City
München
Country
Germany
Facility Name
Medizinisches Zentrum Kreis Aachen
City
Wuerselen
Country
Germany
Facility Name
Anthea Casa di Cura
City
Bari
Country
Italy
Facility Name
Istituto Ortopedico Galeazzi
City
Milan
Country
Italy
Facility Name
St. Luke Hospital, University of Rzeszow, dept of Neurosurgery
City
Tarnow
Country
Poland
Facility Name
Hospital Universitari Bellvitge
City
Barcelona
Country
Spain
Facility Name
Hospital de León
City
Leon
Country
Spain
Facility Name
Hôpital Fribourgeois
City
Fribourg
Country
Switzerland
Facility Name
Hôpitaux Universitaires de Genève
City
Geneva
Country
Switzerland
Facility Name
Hirslanden Klinik St. Anna
City
Lucerne
Country
Switzerland
Facility Name
Chase Farm Hospital
City
Enfield
Country
United Kingdom
Facility Name
St. Georges Hospital
City
London
Country
United Kingdom
Facility Name
Greater Manchester Neuroscience Center
City
Salford
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease

We'll reach out to this number within 24 hrs